Life Science Investing Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Life Science Investing Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Standard Uranium Retains 100% Unencumbered Ownership of the Sun Dog Project Through Conclusion of Property Option Agreement
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
